Matsui Hidenori, Suzuki Masato, Isshiki Yasunori, Kodama Chie, Eguchi Masahiro, Kikuchi Yuji, Motokawa Kenji, Takaya Akiko, Tomoyasu Toshifumi, Yamamoto Tomoko
Laboratory of Immunoregulation, Department of Infection Control and Immunology, Kitasato Institute for Life Sciences, Kitasato University, Minato-ku, Tokyo 108-8641, Japan.
Infect Immun. 2003 Jan;71(1):30-9. doi: 10.1128/IAI.71.1.30-39.2003.
We evaluated the efficacy of mutants with a deletion of the stress response protease gene as candidates for live oral vaccine strains against Salmonella infection through infection studies with mice by using a Salmonella enterica serovar Typhimurium mutant with a disruption of the ClpXP or Lon protease. In vitro, the ClpXP protease regulates flagellum synthesis and the ClpXP-deficient mutant strain exhibits hyperflagellated bacterial cells (T. Tomoyasu et al., J. Bacteriol. 184:645-653, 2002). On the other hand, the Lon protease negatively regulates the efficacy of invading epithelial cells and the expression of invasion genes (A. Takaya et al., J. Bacteriol. 184:224-232, 2002). When 5-week-old BALB/c mice were orally administered 5 x 10(8) CFU of the ClpXP- or Lon-deficient strain, bacteria were detected with 10(3) to 10(4) CFU in the spleen, mesenteric lymph nodes, Peyer's patches, and cecum 1 week after inoculation and the bacteria then decreased gradually in each tissue. Significant increases of lipopolysaccharide-specific immunoglobulin G (IgG) and secretory IgA were detected at week 4 and maintained until at least week 12 after inoculation in serum and bile, respectively. Immunization with the ClpXP- or Lon-deficient strain protected mice against oral challenge with the serovar Typhimurium virulent strain. Both the challenged virulent and immunized avirulent salmonellae were completely cleared from the spleen, mesenteric lymph nodes, Peyer's patches, and even cecum 5 days after the challenge. These data indicate that Salmonella with a disruption of the ATP-dependent protease ClpXP or Lon can be useful in developing a live vaccine strain.
我们通过用鼠伤寒沙门氏菌ClpXP或Lon蛋白酶缺失突变体对小鼠进行感染研究,评估了应激反应蛋白酶基因缺失的突变体作为抗沙门氏菌感染的口服活疫苗株候选物的效力。在体外,ClpXP蛋白酶调节鞭毛合成,ClpXP缺陷突变株表现出细菌细胞鞭毛增多(T. Tomoyasu等人,《细菌学杂志》184:645 - 653,2002年)。另一方面,Lon蛋白酶负向调节侵袭上皮细胞的效力和侵袭基因的表达(A. Takaya等人,《细菌学杂志》184:224 - 232,2002年)。当给5周龄的BALB/c小鼠口服5×10⁸CFU的ClpXP或Lon缺陷株时,接种后1周在脾脏、肠系膜淋巴结、派伊尔结和盲肠中检测到细菌数量为10³至10⁴CFU,随后各组织中的细菌数量逐渐减少。在接种后第4周检测到脂多糖特异性免疫球蛋白G(IgG)和分泌型IgA显著增加,且分别在血清和胆汁中至少维持到第12周。用ClpXP或Lon缺陷株免疫可保护小鼠免受鼠伤寒血清型强毒株的口服攻击。攻击后5天,受攻击的强毒沙门氏菌和免疫的无毒沙门氏菌均从脾脏、肠系膜淋巴结、派伊尔结甚至盲肠中完全清除。这些数据表明,ATP依赖性蛋白酶ClpXP或Lon缺失的沙门氏菌可用于开发口服活疫苗株。